SCHEMBL3014333

SCHEMBL3014333

COc1ccc(Cl)cc1S(=O)(=O)N1CCN(c2nc(Cc3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
KDM4E B2RXH2 1/20 0.54
POLB P06746 1/20 0.54
HPGD P15428 1/20 0.54
RAB9A P51151 1/20 0.54
LMNA P02545 5/20 0.53
MAPT P10636 4/20 0.53
TSHR P16473 2/20 0.53
CYP3A4 P08684 2/20 0.52
CYP2C19 P33261 2/20 0.52
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46
GAA P10253 2/20 0.46
HTT P42858 2/20 0.46
MAPK1 P28482 1/20 0.44
ALOX12 P18054 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012765 0.95 ALDH1A1 (0.52) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3653907 0.94 KMT2A (0.48) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3012761 0.94 GAA (0.49) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3008922 0.91 ALDH1A1 (0.50) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3008166 0.91 LMNA (0.54) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3015393 0.91 ALDH1A1 (0.54) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3019561 0.90 ALDH1A1 (0.51) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3005319 0.90 ALDH1A1 (0.53) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3002552 0.89 ALDH1A1 (0.50) ALDH1A1KDM4EPOLBHPGDRAB9A
SCHEMBL3016382 0.89 ALDH1A1 (0.43) ALDH1A1KDM4EPOLBHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885KDM4E 4398/4885POLB 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.